Adamis Pharmaceuticals Corp expected to post a loss of 6 cents a share - Earnings Preview

DMK Pharmaceuticals

17/09/2021 21:30

* Adamis Pharmaceuticals Corp  ADMP.OQ   ADMP.O  is expected
to show a fall in quarterly revenue when it reports results on
September 20 (estimated). 
* The San Diego, California-based company is expected to report 
a 25.7% decrease in revenue to $3.466 million from $4.66 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Adamis Pharmaceuticals
Corp is for a loss of 6 cents per share. For the same quarter
last year, the company reported a loss of 15 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020              -0.06      -0.24     Missed  -300
 Sep. 30 2020  -0.09       -0.05      -0.10     Missed  -87.5
 Jun. 30 2020  -0.08       -0.08      -0.13     Missed  -69.6​
 Mar. 31 2020  -0.07       -0.06      -0.15     Missed  -164.7
 Dec.          ​           -0.04      -0.08     Missed  -118.2
 31​ 2019​                                              ​
 Sep. 30 2019  -0.10       -0.08      -0.12     Missed  -41.2​
 Jun. 30 2019  -0.14       -0.13      -0.16     Missed  -23.1
 Mar. 31 2019  -0.17       -0.16      -0.19     Missed  -15.2
 This summary was machine generated September 17 at 20:30 GMT. 
All figures in US dollars unless otherwise stated